Telomir Pharmaceuticals, Inc. Common Stock
NASDAQ:TELOBiotechnology
-$0.04 today
- Market cap
- $50.84M
- Beta
- -0.24
- P/E (TTM)
- -3.8
- EPS (TTM)
- -$0.27
Volume 0.17M
Average 0.13M
TELO Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Telomir Pharmaceuticals, Inc. Common StockNASDAQ: TELO
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents rises 1279.8% from a year ago
Cash & equivalents stood at $5.56M at the end of Q1 FY2026, up 1279.8% from a year earlier and down 23.7% from the prior quarter. Over 3 fiscal years it compounded at +1625.2% a year.
Context
- Cash & equivalents amounted to 96.0% of total assets at the end of Q1 FY2026, up 14.0 pp from a year earlier.
- Cash & equivalents increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +1279.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 7.29M USD
- Year-over-year change
- +475.5%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 7.29M | +475.5% |
| FY2024 | 2024-12-31 | 1.27M | +102753.9% |
| FY2023 | 2023-12-31 | 1.23K | -13.2% |
| FY2022 | 2022-12-31 | 1.42K | — |
| FY2021 | 2021-12-31 | 0 | — |
Cash & Equivalents vs competitors
How TELO compares with its peers on the latest reported figures
- TELO's Mar 2026 cash & equivalents of $5.56M is the 5th highest of the 6 companies compared; the peer median is $51.05M.
- Its year-over-year change of +1279.8% is the highest of 6, against a peer median of +22.1%.
- Cash & equivalents amounts to 96.0% of total assets for TELO, versus a peer median of 69.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $90.85M | +134.3% | -23.5% | 69.1% | |
| Mar 2026 | $61.32M | +322.9% | -20.0% | 97.2% | |
| Mar 2026 | $51.05M | -1.6% | -9.8% | 15.6% | |
| Mar 2026 | $21.36M | +10.5% | -22.0% | 82.7% | |
| Mar 2026 | $5.56M | +1279.8% | +1625.2% | 96.0% | |
| Mar 2026 | $5.21M | +22.1% | +14.4% | 26.3% | |
| Peer median (excluding TELO) | $51.05M | +22.1% | -20.0% | 69.1% | |
Competitors are the stored peer set for TELO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Telomir Pharmaceuticals, Inc. Common Stock
NASDAQ:TELO
Intrinsic Alpha fair value
Locked
Current Price
$0.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.